7NS0 Stock Chart & Stats
€5.01
€0.00(0.00%)
At close: 4:00 PM EDT
€5.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.01 - €5.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€309.84M
Enterprise Value€316.62
Total Cash (Recent Filing)€125.17M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding174,270,550
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.03Price Target Upside20.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.19
Revenue Forecast (FY)€369.34K
Bulls Say, Bears Say
Bulls Say
Balance-sheet StrengthLow leverage and a sizable equity base give Palisade structural financial flexibility uncommon for pre-revenue biotechs. This supports continued R&D spending and reduces near-term refinancing risk, lengthening the runway for clinical programs and strategic optionality over months.
FDA Clearance To Start UC StudyRegulatory clearance to start an ulcerative colitis study is a structural milestone: it enables formal clinical progress toward pivotal evidence, de-risks the program's regulatory path, and can materially improve partner/investor engagement and enrollment timelines over the next several months.
Shareholder Support And Financing FlexibilityShareholder approval for charter amendments and equity plans signals governance support and provides deliberate capital-raising tools. This increases the company's ability to fund development, grant incentives, or pursue deals without immediate ad-hoc approvals, improving strategic flexibility.
Bears Say
Pre-revenue With Widening LossesThe company remains essentially pre-revenue while operating losses roughly doubled year-over-year. Persistent negative profitability and rising spending compress returns and increase reliance on external capital, pressuring the business if clinical progress or funding access slows.
Negative Free Cash Flow And Rising BurnSustained negative operating and free cash flow, with a material step-up in burn, creates structural funding risk. If the trend persists, management will likely need to raise capital within months, which can force dilution or constrain program execution and strategic choices.
Heightened Dilution Risk From Charter ChangesExpanded authorized shares and approved equity plans increase the probability of future dilution—a structural downside given the company's cash burn and pre-revenue status. Capital raises or equity-based compensation over the next 2-6 months may dilute existing holders and affect per-share economics.
Palisade Bio News
7NS0 FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is €309.84M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Nov 16, 2026 which is in 63 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 10, 2026. The company reported -€0.043 earnings per share for the quarter, beating the consensus estimate of -€0.045 by €0.002.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 174,270,550 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -€0.043 in its last earnings report, beating expectations of -€0.045. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in DE:7NS0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€6.03 (20.31% Upside)
€6.03 (20.31% Upside)
Blogger Sentiment
Bullish
DE:7NS0 Sentiment 100%
Sector Average 62%
Sector Average 62%
Insider Transactions
Bought Shares
Worth €215.0K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
253.95%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1809.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
7NS0 Stock 12 Month Forecast
Average Price Target
€6.03
▲(20.31% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―